Biotech SF: Cerus to pursue U.S. approval of plasma safety system

Wednesday, November 7, 2012

Cerus to pursue U.S. approval of plasma safety system

The Food and Drug Administration will allow Cerus Corp. to submit a premarket application toward approval of its blood safety system, the company said Wednesday.

More than 80 blood centers in 17 European and Middle Eastern countries use the Concord-based company's (NASDAQ: CERS) Intercept system to neutralize pathogens in platelets and/or plasma, the clear yellowish liquids essential for clotting. But because two studies failed and a collaboration with Baxter fell apart, Cerus hasn't been able to win U.S. approval for its system for screening platelets, plasma or red blood cells.

No comments:

Post a Comment

Some of my favorite stories.

• "The fight of his life" (2007)

Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)

Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)

Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)

Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.

All he needs now is $20 million.